Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.

Tevogen Bio Announces Series A-1 Preferred Stock Investment The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.

ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023 ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023 Interim data from EVICTION-2 study confirms safety and tolerability...

Hyris' New T-Cell Test is Finally Available to EU Countries to Easily Map Patients' Cellular Immunity to SARS-CoV-2 LONDON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- As the pandemic crisis has entered a new phase, it is a common belief among the scientific community that COVID-19 is here to stay, maybe for a long time....

T-Cell Surface Glycoprotein CD4 Clinical Trial Analysis by DelveInsight Los Angeles, USA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- T-Cell Surface Glycoprotein CD4 Clinical Trial Analysis by DelveInsight     DelveInsight has recently added “T-cell Surface Glycoprotein CD4 –...